![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fleu.2015.205/MediaObjects/41375_2015_Article_BFleu2015205_Fig1_HTML.jpg)
References
Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA . Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 2014; 92: 289–297.
Hasle H . Incidence of essential thrombocythaemia in children. Br J Haematol 2000; 110: 751.
Giona F, Teofili L, Moleti ML, Martini M, Palumbo G, Amendola et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood 2012; 119: 2219–2227.
Kucine N, Chastain KM, Mahler MB, Bussel JB . Primary thrombocytosis in children. Haematologica 2014; 99: 620–628.
Randi ML, Putti MC, Scapin M, Pacquola E, Tucci F, Micalizzi C et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006; 108: 3600–3602.
Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007; 25: 1048–1053.
Langabeer SE, Haslam K, McMahon C . CALR mutations are rare in childhood essential thrombocythemia. Pediatr Blood Cancer 2014; 61: 1523.
Giona F, Teofili L, Capodimonti S, Laurino M, Martini M, Marzella D et al. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood 2014; 123: 3677–3679.
Langabeer SE, Haslam K, McMahon C . Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia. Pediatr Blood Cancer 2014; 62: 175–176.
Randi ML, Geranio G, Bertozzi I, Micalizzi C, Ramenghi U, Tucci F et al. Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort. Br J Haematol 2015; 169: 584–589.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.
Tefferi A, Thiele J, Vannucchi AM, Barbui T . An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014; 28: 1407–1413.
Fu R, Zhang L, Yang R . Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. Br J Haematol 2013; 163: 295–302.
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123: 2220–2228.
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405.
Konieczna I, Horvath E, Wang H, Lindsey S, Saberwal G, Bei L et al. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest 2008; 118: 853–867.
Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 2003; 12: 1239–1250.
Hilton DJ, Watowich SS, Katz L, Lodish HF . Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor. J Biol Chem 1996; 271: 4699–4708.
Acknowledgements
We thank Stefan Constantinescu for helpful advice on the candidate mutations in EPOR. This work was funded by grants 310000-120724/1 and 32003BB_135712/1 from the Swiss National Science Foundation and the Swiss Cancer League (KLS-2950-02-2012) to RCS.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website .
Supplementary information
Rights and permissions
About this article
Cite this article
Karow, A., Nienhold, R., Lundberg, P. et al. Mutational profile of childhood myeloproliferative neoplasms. Leukemia 29, 2407–2409 (2015). https://doi.org/10.1038/leu.2015.205
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.205
- Springer Nature Limited
This article is cited by
-
Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study
Leukemia (2024)
-
IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia
Frontiers of Medicine (2022)
-
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms
Annals of Hematology (2021)
-
The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters
Leukemia (2019)
-
Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender
Current Hematologic Malignancy Reports (2017)